A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization.
Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal antibody shuts down receptor signaling and has potent antitumor activity even in tumors that express low levels of ErbB2, a finding that could result in a larger number of patients benefiting from anti-ErbB2 therapies.